The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
23h
The United States contributed to the Epidermolysis Bullo's highest prevalent cases, accounting for ~65% of the 7MM in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback